Goodman Noah (CIK 2060075) reported 14 SEC Form 4 insider transactions across 1 companies over the past 18 months (most recent 2026-07-02). Recent activity: Sell KYMR (3,389 shares), Buy KYMR (5,000 shares), Sell KYMR (2,500 shares), Sell KYMR (2,500 shares), Buy KYMR (2,500 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-02 | Kymera Therapeutics, Inc. (KYMR) | Chief Business Officer | Sell | 3,389 | $387,329 |
| 2026-06-25 | Kymera Therapeutics, Inc. (KYMR) | Chief Business Officer | Buy | 5,000 | $105,250 |
| 2026-06-25 | Kymera Therapeutics, Inc. (KYMR) | Chief Business Officer | Sell | 2,500 | $272,500 |
| 2026-06-25 | Kymera Therapeutics, Inc. (KYMR) | Chief Business Officer | Sell | 2,500 | $297,500 |
| 2026-06-22 | Kymera Therapeutics, Inc. (KYMR) | Chief Business Officer | Buy | 2,500 | $52,625 |
| 2026-06-22 | Kymera Therapeutics, Inc. (KYMR) | Chief Business Officer | Sell | 2,500 | $247,500 |
| 2026-04-16 | Kymera Therapeutics, Inc. (KYMR) | Chief Business Officer | Sell | 1,347 | $121,230 |
| 2026-04-10 | Kymera Therapeutics, Inc. (KYMR) | Chief Business Officer | Buy | 2,500 | $52,625 |
| 2026-04-10 | Kymera Therapeutics, Inc. (KYMR) | Chief Business Officer | Sell | 3,094 | $267,996 |
| 2026-04-10 | Kymera Therapeutics, Inc. (KYMR) | Chief Business Officer | Sell | 2,670 | $232,586 |
| 2026-04-10 | Kymera Therapeutics, Inc. (KYMR) | Chief Business Officer | Sell | 2,500 | $222,500 |
| 2026-04-10 | Kymera Therapeutics, Inc. (KYMR) | Chief Business Officer | Sell | 2,000 | $174,700 |
| 2026-03-04 | Kymera Therapeutics, Inc. (KYMR) | Chief Business Officer | Buy | 9,225 | $0 |
| 2025-04-09 | Kymera Therapeutics, Inc. (KYMR) | Chief Business Officer | Buy | 50,000 | $0 |
Source: SEC Form 4 filings · as of 2026-07-02